// App-Quantinova.ai

Mo1325 : Cost-Effectiveness of Infliximab Scheduled Maintenance Treatment for the Management of Patients With Moderate-to-Severe Ulcerative Colitis

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • N/A

Medical Centers

  • Robarts Clinical Trials, University of Western Ontario, London, Ontario, Canada

Locations

  • Canada

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved